Latest News

AstraZeneca indications $1.92 bln licencing handle HK-listed CSPC

AstraZeneca said on Monday it would pay up to $1.92 billion to CSPC Pharmaceutical Group Ltd. in a special licence contract to enhance the. AngloSwedish drugmaker's cardiovascular pipeline.

Apart from the aforementioned turning point and royalty payment,. Hong Kong-based CSPC will likewise get an in advance payment of $100. million as part of the offer.

CSPC will develop an early-stage, unique small molecule. Lipoprotein (a) disruptor, which might provide benefits to. clients with high levels of bad cholesterol, AstraZeneca. said.

Lp( a) is a type of low-density lipoprotein that plays a role. in carrying cholesterol in the blood stream.

AstraZeneca said it would have access to CSPC's pre-clinical. candidate little particle - YS2302018 - an oral Lp( a) disruptor,. with the objective to establish it as a lipid-lowering treatment.

The asset might help attend to the significant threat factors driving. chronic heart diseases, alone or in mix with. other drugs, consisting of AstraZeneca's oral little particle PCSK9. inhibitor AZD0780, it stated.

AZD0780 is being established as a treatment for clients with. dyslipidaemia that can not be managed alone by statins, which. are drugs that lower blood cholesterol. PSCK9 is a widely known. and confirmed target in lipid metabolism.

(source: Reuters)